Companies › Oculis
2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 3; Ophthalmology, Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Privosegtor (OCS-05) Neuroprotective candidate | – | Phase 3 | Optic Neuritis | Dec 2027 |
| licaminlimab Anti-ICAM-1 antibody | ICAM1 | Phase 2 | Dry Eye Disease (DED) | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07548632 | licaminlimab | Phase 2 | Dry Eye Disease (DED) | Ophthalmology | Dec 2026 |
| NCT07623668 | Privosegtor (OCS-05) | Phase 3 | Optic Neuritis | Neurology | Dec 2027 |
Cash and short-term investments of 82m CHF on 2025-12-31; operating cash outflow about 66m CHF a year; runway about 15 months at that burn, to Mar 2027; 1 of 2 coming phase 2-3 readouts fall inside that runway
–
Annexon Immunovant Sciences Coya Therapeutics NervGen Pharma Cognition Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.